Ombitasvir
Ombitasvir is an antiviral drug for the treatment of hepatitis C virus infection by AbbVie. In the United States, it is approved by the Food and Drug Administration for use in combination with paritaprevir, ritonavir and dasabuvir in the product Viekira Pak for the treatment of HCV genotype 1, and with paritaprevir and ritonavir in the product Technivie for the treatment of HCV genotype 4.
Ombitasvir is an NS5A inhibitor that acts by inhibiting the HCV protein NS5A.
